Dr Reddy's Laboratories. Share Price
Free Demat with Zero AMC*
+ Free 1st Year AMC
Summary
The stock has recorded a trading volume of 26,07,818 shares,. Its Average Traded Price (ATP) is ₹1212.15, while the Last Traded Quantity at the Last Traded Price (LTQ@LTP) is 13 @ ₹1206.20.
Dr Reddy's Laboratories. has an upper circuit limit of ₹1326.80 and a lower circuit limit of ₹1085.60. The total value traded stands at ₹316.11 CR, and the delivery percentage for the day is 60.08%.
The stock is currently traded with a market lot size of 1. Dr Reddy's Laboratories. also offers a dividend yield of 0.65%.
Dr Reddy's Laboratories Share Price Chart
Dr Reddy's Laboratories. Share Key Metrics
Volume
26.08 L
Market Cap
100679.14 CR
LTQ@LTP
13@1206.20
ATP
1212.15
Var Margin
12.57 %
Circuit Range
1085.6-1326.8
Delivery %
60.08 %
Value
316.11 CR
ASM/GSM
No
Market Lot
1
Dr Reddy's Laboratories. Resistance and Support
Pivot 1230.6
Resistance
First Resistance
1247
Second Resistance
1261
Third Resistance
1277.4
Support
First Support
1216.6
Second Support
1200.2
Third Support
1186.2
Dr Reddy's Laboratories. Futures & Options
1206.2
-26.8 (-2.17%)
Dr Reddy's Laboratories. Option Chain
View Price, OI, Greeks & More...
27OCT26
1212.90
-14.30 (1.17%)
23NOV26
1206.30
-19.70 (1.61%)
29DEC26
1205.00
-20.00 (1.63%)
DRREDDY|27OCT26 CE 1200.00
39.00
-9.5 (-19.59%)
DRREDDY|27OCT26 PE 1210.00
33.6
8.05 (31.51%)
Dr Reddy's Laboratories. Shareholding Pattern
View More- 2016-17
- 2017-18
- 2018-19
- 2019-20
- 2020-21
- 2021-22
- 2022-23
- 2023-24
- 2024-25
- 2025-26
- 2026-27
Total Promoters
Dr Reddy's Laboratories. Corporate Actions
| Date | Agenda |
|---|---|
| 2026-10-23 | Quarterly Results |
| 2026-07-22 | Quarterly Results |
| 2026-05-12 | Audited Results |
| 2026-01-21 | Quarterly Results |
| 2025-10-24 | Quarterly Results |
| 2025-07-23 | Quarterly Results |
| 2025-05-09 | Audited Results |
| 2025-01-23 | Quarterly Results |
| 2024-11-05 | Quarterly Results |
| 2024-07-27 | Quarterly Results & Stock Split |
| Ex Date | Record Date | |
|---|---|---|
| 2026-07-10 | 2026-07-10 | View More |
| Split Ratio | Split Date | |
|---|---|---|
| 5:1 | 2024-10-28 | View More |
Dr Reddy's Laboratories. News
Dr Reddys Laboratories Ltd - 500124 - Board Meeting Intimation for Approval Of Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ending September 30, 2026.
Dr. Reddy's Laboratories has scheduled a board meeting on October 23, 2026, to consider and approve the standalone and consolidated financial results for the quarter ended September 30, 2026.
Sep 22 2026 16:58:26
Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Dr Reddys Laboratories management will engage in an in-person group investor meeting with Nomura in Hyderabad on September 25, 2026. This routine interaction provides an opportunity for investors to engage directly with the company.
Sep 21 2026 16:51:02
Dr Reddys Laboratories Ltd - 500124 - Clarification-Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
Dr. Reddy's Laboratories clarified and confirmed a news report regarding a voluntary licensing agreement with Gilead Sciences. The agreement is for investigational once-yearly lenacapavir, an HIV prevention drug, expanding their existing collaboration.
Sep 18 2026 08:41:31
Dr Reddys Laboratories Ltd - 500124 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
Dr Reddys Laboratories received two observations on Form FDA 2953 from the USFDA following a records assessment at its API manufacturing facility in Jiutepec, Morelos, Mexico. The company will respond to these observations within the stipulated timeline.
Sep 11 2026 22:07:43
Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Dr. Reddy's Laboratories management is scheduled to participate in two investor group meetings. The first is with ICICI Securities in Hyderabad on September 17, 2026, and the second is a virtual meeting with Bank of America on September 24, 2026.
Sep 10 2026 17:36:19
Dr Reddy's Laboratories. Management
| Name | Position |
|---|---|
| K Randhir Singh | Company Secretary, Compliance Officer and Head-CSR |
| K Satish Reddy | Chairman |
Dr Reddy's Laboratories. Similar Stocks
Zydus Lifesciences Ltd.
1145.70
-16.30 (1.40%)
Lenskart Solutions Ltd.
691.15
6.10 (0.89%)
Cipla Ltd.
1344.00
-2.00 (0.15%)
Laurus Labs Ltd.
1984.00
4.00 (0.20%)
Mankind Pharma Ltd.
2535.00
31.20 (1.25%)
Manipal Health Enterprises Ltd.
696.00
-12.30 (1.74%)
Aurobindo Pharma Ltd.
1676.80
4.80 (0.29%)
Max Healthcare Institute Ltd.
940.95
11.15 (1.20%)
Lupin Ltd.
2031.20
1.00 (0.05%)
Glenmark Pharmaceuticals Ltd.
2331.00
-3.70 (0.16%)
Dr Reddy's Laboratories. FAQs
Open Your Free
Demat Account Now!
AMC for First Year
Auto Square Off Charges
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools

Open Your Free
Demat Account Now!
AMC For First Year
Account Opening Fee
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools
Invest in DRREDDY
Account Opening Fee AMC for 1st Year Auto Square Off Charges Call & Trade
+ Free 1st Year AMC